364 related articles for article (PubMed ID: 17708397)
1. Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs.
Lana S; U'ren L; Plaza S; Elmslie R; Gustafson D; Morley P; Dow S
J Vet Intern Med; 2007; 21(4):764-9. PubMed ID: 17708397
[TBL] [Abstract][Full Text] [Related]
2. Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma.
Gardner HL; London CA; Portela RA; Nguyen S; Rosenberg MP; Klein MK; Clifford C; Thamm DH; Vail DM; Bergman P; Crawford-Jakubiak M; Henry C; Locke J; Garrett LD
BMC Vet Res; 2015 Jun; 11():131. PubMed ID: 26062540
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma.
U'Ren LW; Biller BJ; Elmslie RE; Thamm DH; Dow SW
J Vet Intern Med; 2007; 21(1):113-20. PubMed ID: 17338158
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant anthracycline-based vs metronomic chemotherapy vs no medical treatment for dogs with metastatic splenic hemangiosarcoma: A multi-institutional retrospective study of the Italian Society of Veterinary Oncology.
Marconato L; Chalfon C; Finotello R; Polton G; Vasconi ME; Annoni M; Stefanello D; Mesto P; Capitani O; Agnoli C; Amati M; Sabattini S
Vet Comp Oncol; 2019 Dec; 17(4):537-544. PubMed ID: 31251441
[TBL] [Abstract][Full Text] [Related]
5. Clinical and pharmacokinetic characteristics of intracavitary administration of pegylated liposomal encapsulated doxorubicin in dogs with splenic hemangiosarcoma.
Sorenmo K; Samluk M; Clifford C; Baez J; Barrett JS; Poppenga R; Overley B; Skorupski K; Oberthaler K; Van Winkle T; Seiler G; Shofer F
J Vet Intern Med; 2007; 21(6):1347-54. PubMed ID: 18196746
[TBL] [Abstract][Full Text] [Related]
6. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial.
Vail DM; MacEwen EG; Kurzman ID; Dubielzig RR; Helfand SC; Kisseberth WC; London CA; Obradovich JE; Madewell BR; Rodriguez CO
Clin Cancer Res; 1995 Oct; 1(10):1165-70. PubMed ID: 9815908
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin and deracoxib adjuvant therapy for canine splenic hemangiosarcoma: a pilot study.
Kahn SA; Mullin CM; de Lorimier LP; Burgess KE; Risbon RE; Fred RM; Drobatz K; Clifford CA
Can Vet J; 2013 Mar; 54(3):237-42. PubMed ID: 23997259
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant Doxorubicin with or without Metronomic Cyclophosphamide for Canine Splenic Hemangiosarcoma.
Matsuyama A; Poirier VJ; Mantovani F; Foster RA; Mutsaers AJ
J Am Anim Hosp Assoc; 2017; 53(6):304-312. PubMed ID: 28892429
[TBL] [Abstract][Full Text] [Related]
9. Canine visceral hemangiosarcoma treated with surgery alone or surgery and doxorubicin: 37 cases (2005-2014).
Batschinski K; Nobre A; Vargas-Mendez E; Tedardi MV; Cirillo J; Cestari G; Ubukata R; Dagli MLZ
Can Vet J; 2018 Sep; 59(9):967-972. PubMed ID: 30197439
[TBL] [Abstract][Full Text] [Related]
10. Epirubicin in the adjuvant treatment of splenic hemangiosarcoma in dogs: 59 cases (1997-2004).
Kim SE; Liptak JM; Gall TT; Monteith GJ; Woods JP
J Am Vet Med Assoc; 2007 Nov; 231(10):1550-7. PubMed ID: 18021000
[TBL] [Abstract][Full Text] [Related]
11. Survival time of dogs with splenic hemangiosarcoma treated by splenectomy with or without adjuvant chemotherapy: 208 cases (2001-2012).
Wendelburg KM; Price LL; Burgess KE; Lyons JA; Lew FH; Berg J
J Am Vet Med Assoc; 2015 Aug; 247(4):393-403. PubMed ID: 26225611
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and toxicity of VAC chemotherapy (vincristine, doxorubicin, and cyclophosphamide) in dogs with hemangiosarcoma.
Hammer AS; Couto CG; Filppi J; Getzy D; Shank K
J Vet Intern Med; 1991; 5(3):160-6. PubMed ID: 1920253
[TBL] [Abstract][Full Text] [Related]
13. Surgery and doxorubicin in dogs with hemangiosarcoma.
Ogilvie GK; Powers BE; Mallinckrodt CH; Withrow SJ
J Vet Intern Med; 1996; 10(6):379-84. PubMed ID: 8947871
[TBL] [Abstract][Full Text] [Related]
14. A randomized controlled study into the efficacy and toxicity of pegylated liposome encapsulated doxorubicin as an adjuvant therapy in dogs with splenic haemangiosarcoma.
Teske E; Rutteman GR; Kirpenstein J; Hirschberger J
Vet Comp Oncol; 2011 Dec; 9(4):283-9. PubMed ID: 22077409
[TBL] [Abstract][Full Text] [Related]
15. VAC protocol for treatment of dogs with stage III hemangiosarcoma.
Alvarez FJ; Hosoya K; Lara-Garcia A; Kisseberth W; Couto G
J Am Anim Hosp Assoc; 2013; 49(6):370-7. PubMed ID: 24051260
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and toxicity of a dose-intensified doxorubicin protocol in canine hemangiosarcoma.
Sorenmo KU; Baez JL; Clifford CA; Mauldin E; Overley B; Skorupski K; Bachman R; Samluk M; Shofer F
J Vet Intern Med; 2004; 18(2):209-13. PubMed ID: 15058772
[TBL] [Abstract][Full Text] [Related]
17. Comparison of doxorubicin-cyclophosphamide with doxorubicin-dacarbazine for the adjuvant treatment of canine hemangiosarcoma.
Finotello R; Stefanello D; Zini E; Marconato L
Vet Comp Oncol; 2017 Mar; 15(1):25-35. PubMed ID: 25623994
[TBL] [Abstract][Full Text] [Related]
18. Impact of repeated cycles of EGF bispecific angiotoxin (eBAT) administered at a reduced interval from doxorubicin chemotherapy in dogs with splenic haemangiosarcoma.
Borgatti A; Fieberg A; Winter AL; Stuebner K; Taras E; Todhunter D; Masyr A; Rendhal A; Vallera DA; Koopmeiners JS; Modiano JF
Vet Comp Oncol; 2020 Dec; 18(4):664-674. PubMed ID: 32187827
[TBL] [Abstract][Full Text] [Related]
19. Retrospective comparison of first-line adjuvant anthracycline vs metronomic-based chemotherapy protocols in the treatment of stage I and II canine splenic haemangiosarcoma.
Treggiari E; Borrego JF; Gramer I; Valenti P; Harper A; Finotello R; Toni C; Laomedonte P; Romanelli G
Vet Comp Oncol; 2020 Mar; 18(1):43-51. PubMed ID: 31648405
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the anti-tumour activity of Coriolus versicolor polysaccharopeptide (I'm-Yunity) alone or in combination with doxorubicin for canine splenic hemangiosarcoma.
Gedney A; Salah P; Mahoney JA; Krick E; Martins R; Scavello H; Lenz JA; Atherton MJ
Vet Comp Oncol; 2022 Sep; 20(3):688-696. PubMed ID: 35442554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
